Cocrystal Pharma, Inc. — Form 8-K
Filed August 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K filed 2026-08-18 reports Item 5.02 regarding departure of directors or officers and compensatory arrangements of certain officers, and Item 9.01 financial statements/exhibits. No specific names, dollar amounts, dates, or details of the compensation or departures are provided in the filing header or accessible document summary.
Why this rating
Officer/director changes are routine disclosures; without concrete dollar amounts or strategic context, impact is minimal for $11.6M company.
Extracted items
- 5.02 exec change
- 9.01 exhibits
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.